A61K 51 - Preparations containing radioactive substances for use in therapy or testing in vivo

Patents for A61K 51 - Preparations containing radioactive substances for use in therapy or testing in vivo (24,291)
11/2002
11/06/2002	CN1378446A Method of inhibiting amyloid protein aggregation and imaging amyloid deposits
11/05/2002	US6476016 Inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation
11/05/2002	US6475745 Identification of agents that protect against inflammatory injury to neurons
11/05/2002	US6475742 Prevention complexing
11/05/2002	US6475644 Medical devices for delivery of targeted radioisotopes
11/02/2002	CA2346154A1 Gastrin receptor-avid peptide conjugates
10/2002
10/31/2002	WO2002086449A2 Systems, methods and devices for in vivo monitoring of a localized response via a radiolabeled analyte in a subject
10/31/2002	WO2002086093A2 Methods of using a hyaluronan receptor
10/31/2002	WO2002085908A1 Folate mimetics and folate-receptor binding conjugates thereof
10/31/2002	WO2002085903A2 Amyloid plaque aggregation inhibitors and diagnostic imaging agents
10/31/2002	WO2002085418A2 Tc and re labeler radioactive glycosylated octreotide derivatives
10/31/2002	WO2002007781A3 Amyloid targeting imaging agents and uses thereof
10/31/2002	WO2001091806A3 Measurement of the therapeutic dose for bone marrow ablation therapy
10/31/2002	WO2001087348A3 Multifunctional nanodevice platform
10/31/2002	WO2001052898A9 Methods for incorporating metal chelators at carboxyl-terminal site of peptides
10/31/2002	WO2001044243A3 Novel heteroaryl-diazabicycloalkanes
10/31/2002	US20020161357 Method and apparatus for EMR treatment
10/31/2002	US20020160999 Treatment of diseases or disorders of the central nervous system
10/31/2002	US20020159996 Use of CD23 antagonists for the treatment of neoplastic disorders
10/31/2002	US20020159951 Administering to the patient a contrast agent comprising, in an aqueous carrier, targeted vesicles formulated from a lipid or polymer, a prfluorocarbon gas, a targeting ligand, scanning the patient using ultrasound to obtain an image
10/31/2002	US20020159950 Reverse isotope dilution assay and lactose intolerance assay
10/31/2002	US20020159949 Assessing the level of dopamine transporter in at least one region of the patient's central nervous system, by binding a dopamine transporter ligand to the dopamine transporters using tomography
10/31/2002	US20020159948 Introducing a chemical compound to a patient, the compound being a complex of a fluorescent marker and a radioactive marker, cells are then collected through noninvasive means, observation of fluorescence indicates cancer or precondition
10/31/2002	US20020159947 Administering a diagnostically effective amount of a radiopharmaceutical inhibitor of amyloid protein precursor (APP) processing and/or the production of beta- amyloid production; imaging the area of disease in a patient
10/31/2002	CA2445627A1 Methods of using a hyaluronan receptor
10/31/2002	CA2444214A1 Amyloid plaque aggregation inhibitors and diagnostic imaging agents
10/30/2002	EP1251901A1 Medical devices that resist restenosis
10/30/2002	EP1251877A1 Site specific binding system, nuclear imaging compositions and methods
10/30/2002	EP1251840A2 Method for using potassium channel activation for delivering a medicant to an abnormal brain region and/or a malignant tumor
10/30/2002	EP0662972B1 3-,8-substituted deuteroporphyrine derivatives, pharmaceuticals containing them and methods of producing them
10/30/2002	CN1093424C Monoamine, diamide, thiol-containingmetal chelating agents
10/29/2002	US6472422 Treating drug addiction
10/29/2002	US6471968 Multifunctional nanodevice platform
10/29/2002	US6471960 Methods for the prevention or treatment of alzheimer's disease
10/24/2002	WO2002083928A2 Nucleid acid and corresponding protein entitled 158p3d2 useful in treatment and detection of cancer
10/24/2002	WO2002083926A2 Methods of diagnosing and treating small intestinal bacterial overgrowth (sibo) and sibo-related conditions
10/24/2002	WO2002083917A2 Nucleic acid and corresponding protein entitled 161p5c5 useful in treatment and detection of cancer
10/24/2002	WO2002083916A2 Nucleic acid and corresponding protein entitled 162p1e6 useful in treatment and detection of cancer
10/24/2002	WO2002083171A2 Cancer treatment by using fap-alpha specific antibodies
10/24/2002	WO2002083150A1 Bisphosphonate conjugates and methods of making and using the same
10/24/2002	WO2002083068A2 Nucleic acid and corresponding protein entitled 121p2a3 useful in treatment and detection of cancer
10/24/2002	WO2002067999A3 Actinium-225 complexes and conjugates for targeted radiotherapy
10/24/2002	WO2002066077A3 Modulated release particles for aerosol delivery
10/24/2002	US20020155576 Compound for use in the treatment and prevention of cell proliferation disorders
10/24/2002	US20020155494 Generating library of ligands; obtain sample with ligand, attach expansion linker, generate ligands
10/24/2002	US20020155064 Administering radiolabelled peptide selected from the group consisting of neurotensin (NT), NT-receptor agonists, NT-receptor antagonists, NT analogues and NT derivatives, subjecting to external imaging, by radioactive scanning
10/24/2002	CA2770489A1 Bisphosphonate conjugates and methods of making and using the same
10/24/2002	CA2444548A1 Methods of diagnosing and treating small intestinal bacterial overgrowth (sibo) and sibo-related conditions
10/24/2002	CA2443141A1 Nucleic acid and corresponding protein entitled 162p1e6 useful in treatment and detection of cancer
10/24/2002	CA2443088A1 Nucleic acid and corresponding protein entitled 121p2a3 useful in treatment and detection of cancer
10/23/2002	EP1250149A1 A novel method of diagnosing, monitoring, staging, imaging and treating cancer
10/23/2002	EP1250091A1 Hydrophilic cyanine dyes
10/23/2002	CN1375332A Composition and method for making Akt cancer gene inactivate and activating P38 precell fade-out gene
10/22/2002	US6469162 Compounds with chelation affinity and selectivity for first transition series elements: use in medical therapy and diagnosis
10/22/2002	US6469146 Radiopharmaceutical products suitable for the selective labeling of lymphocytes, and their preparation
10/22/2002	US6468981 Compound comprising steroid moiety which binds to androgen receptor covalently linked to polycationic salt complexed with nucleic acid capable of therapeutically modifying or revealing presence of androgen receptor-containing cell
10/22/2002	US6468802 Anlyzing expired 13c-labeled (isotopes) carbon monoxide following ingestion of labeled glucose source
10/22/2002	US6468530 Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype
10/22/2002	US6468503 Method and composition for the treatment of cancer by the enzymatic conversion of soluble radioactive toxic precipitates in the cancer
10/22/2002	CA2218477C Rna photocleavage using texaphyrins
10/17/2002	WO2002082044A2 Method of imaging cell death in vivo
10/17/2002	WO2002082041A2 Production and use of novel peptide-based agents for use with bi-specific antibodies
10/17/2002	WO2002081649A2 ErbB INTERFACE PEPTIDOMIMETICS AND METHODS OF USE THEREOF
10/17/2002	WO2002081430A2 Novel benzylideneamino guanidines and their uses as ligands to the melanocortin receptors
10/17/2002	WO2002080987A1 Anti-cd19 immunotoxins
10/17/2002	WO2002080896A1 Uses of benzylideneamino guanidines as ligands to the melanocortiin receptors
10/17/2002	WO2002080754A2 Methods for using annexin for detecting cell death in vivo and treating associated conditions
10/17/2002	WO2002066468A3 Heterocyclic urea derivatives and their use as dopamine d3 receptor ligands
10/17/2002	WO2002010192A9 Somatostatin analogues
10/17/2002	US20020151062 Monitoring efficiency of peptiod to transfect cell; obtain cell, incubate with oligonucleotide and peptiod, monitor efficiency of transfection of oligonucleotide
10/17/2002	US20020150536 Nucleic acid ligands to integrins
10/17/2002	US20020150535 Methods for diagnosing and monitoring treatment ADHD by assessing the dopamine transporter level
10/17/2002	CA2443694A1 Anti-cd19 immunotoxins
10/17/2002	CA2443099A1 Uses of benzylideneamino guanidines as ligands to the melanocortiin receptors
10/17/2002	CA2443057A1 Novel benzylideneamino guanidines and their uses as ligands to the melanocortin receptors
10/17/2002	CA2442839A1 Production and use of novel peptide-based agents for use with bi-specific antibodies
10/17/2002	CA2442382A1 Methods for using annexin for detecting cell death in vivo and treating associated conditions
10/16/2002	CN1374870A Treatment of intermediate-and high-grade non-Hodgkins lymphoma with anti-CD20 antibody
10/15/2002	US6465613 Administering a somatostatin derivative to a patient for selectively targeting and arresting the growth of an angiogenic blood vessel or a cell
10/10/2002	WO2002079429A2 Anti-muc-1 single chain antibodies for tumor targeting
10/10/2002	WO2002079255A1 RECOMBINANT ANTIBODIES COEXPRESSED WITH GnTIII
10/10/2002	WO2002078863A1 Generation of pharmaceutical agent particles using focused acoustic energy
10/10/2002	WO2002078638A2 Morpholino imaging and therapy
10/10/2002	WO2002055111A3 Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent
10/10/2002	WO2002043776A3 Neuropeptide y1 receptor binding compounds in the treatment and diagnosis of cancer
10/10/2002	WO2001080906A3 Radiometal complexes of 2-pyrrolylthiones for imaging a therapy
10/10/2002	WO2001072203A3 Therapy of proliferative disorders by direct irradiation of cell nuclei with tritiated nuclear targeting agents
10/10/2002	WO2001068151A3 Functional radiographic imaging methods and agents
10/10/2002	WO2001053324A8 Novel haptotactic peptides
10/10/2002	US20020147997 Animal model for use in the diagnosis, prevention and treatment of cancer
10/10/2002	US20020147316 Medical diagnosis, therapy
10/10/2002	US20020147136 Tetrapeptide
10/10/2002	US20020146846 Novel method for the stabilization of chimeric immunoglobulins or immunoglobulin fragments, and stabilized anti-EGP-2 scFv fragment
10/10/2002	US20020146761 Detecting gram-negative bacterial infection in human; btain human, inject with labeled endotoxin neutralizing protein, detect label
10/10/2002	US20020146750 Mucin for use in the diagnosiss and treatment of cancer
10/10/2002	US20020146370 Use of protein tyrosine phosphatase zeta as a biomolecular target in the treatment and visualization of brain tumors
10/10/2002	US20020146369 Intraoperative, intravascular and endoscopic tumor and lesion detection, biopsy and therapy
10/10/2002	CA2443138A1 Anti-muc-1 single chain antibodies for tumor targeting
10/10/2002	CA2442801A1 Recombinant antibodies coexpressed with gntiii
10/09/2002	EP1246830A1 Macrocyclic chelants for metallopharmaceuticals

1 ... 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 ... 243